How is REQUIP XL different from other dopamine agonists?
What are the differences between REQUIP XL and immediate-release ropinirole?
What are the benefits of treatment with REQUIP XL?
Can patients be switched from immediate-release ropinirole to
REQUIP XL?
What time of day should REQUIP XL be dosed?
Are there any differences in side effects between REQUIP XL and immediate-release ropinirole?
What is the indication for REQUIP XL?
REQUIP XL Extended-Release Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.Back to Top
How does REQUIP XL work in patients with Parkinson’s disease?
The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain. Researchers have determined that Parkinson’s disease involves pathways in the brain responsible for motor control that are functioning improperly. Patients with Parkinson’s disease experience a reduction in dopamine, a key chemical in the brain that communicates messages about movement, resulting in the symptoms of Parkinson’s disease.Like immediate-release ropinirole, REQUIP XL mimics dopamine, which improves the symptoms of Parkinson’s disease.
REQUIP XL may help reduce symptoms of idiopathic Parkinson’s disease, including improving control of various body movements, which begin to slow or become irregular in early Parkinson’s disease.
Back to Top
How is REQUIP XL different from other dopamine agonists?
REQUIP XL is the first and only oral once-daily dopamine agonist indicated for both early and advanced Parkinson’s disease.Back to Top
What are the differences between REQUIP XL and immediate-release ropinirole?
REQUIP XL is a once-a-day formulation of ropinirole for treating Parkinson’s disease using SkyePharma PLC’s (Nasdaq:SKYE; LSE: SKP) patented GEOMATRIX technology. REQUIP XL has been designed to provide a steady rate of absorption in the body to help reduce daily blood plasma fluctuations. Immediate-release ropinirole is dosed TID. Additionally, REQUIP XL offers physicians and patients a fast and simpler titration schedule compared to immediate-release ropinirole. The starting dose and titration schedules are different between REQUIP XL and immediate-release ropinirole. In a clinical study of early Parkinson's disease patients, REQUIP XL was demonstrated to be non-inferior to immediate-release ropinirole. REQUIP XL and immediate-release ropinirole were generally well tolerated.Back to Top
What are the benefits of treatment with REQUIP XL?
REQUIP XL is the only oral, once-a-day dopamine agonist medication for Parkinson's disease. It may be taken alone or in combination with L-dopa. REQUIP XL can improve symptom control in both early- and late-stage Parkinson's disease.Back to Top
Can patients be switched from immediate-release ropinirole to
REQUIP XL?
Patients may be switched directly from immediate-release ropinirole to REQUIP XL. The initial switching dose of REQUIP XL should most closely match the total daily dose of immediate-release ropinirole.
Back to Top
What time of day should REQUIP XL be dosed?
In clinical trials, it was recommended that patients take their dose of REQUIP XL in the morning.Back to Top
Are there any differences in side effects between REQUIP XL and immediate-release ropinirole?
In general, similar types of adverse reactions are seen with REQUIP XL and immediate-release ropinirole.Please see complete Prescribing Information for Requip® (ropinirole) Tablets and REQUIP XL
Important Safety Information
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL